Engineering a Robust Escherichia coli W Platform for Scalable Production of Flavonoid‐O‐Glucosides
Microbial Biotechnology · 2025-10 · 18 (10)
DOI: 10.1111/1751-7915.70226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 09.10.2025. Verfasst von Darwin Carranza-Saavedra und 8 weiteren Autor:innen. Beteiligte Einrichtung: Systems Biotechnology Group, Department of Systems Biology, Centro Nacional de Biotecnología, CSIC, Madrid, Spain. Hauptthemen laut MEDLINE: Metabolic Engineering, Flavonoids, Escherichia coli, Glucosides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission, Agencia Estatal de Investigación.
Abstract (Originalsprache)
Flavonoids are valuable for pharmaceutical, cosmetic and food applications. However, poor solubility and bioavailability limit their widespread use. Biotechnological glycosylation of flavonoids helps address these limitations, but such bioprocesses remain constrained by the cost and availability of uridine diphosphate glucose (UDPG) and the inherent toxicity of flavonoids. In this study we demonstrate that Escherichia coli W is an optimal microbial host for glycosylation bioprocesses using sucrose as a carbon and UDPG source. Escherichia coli W outperforms the model E. coli K12 strain in terms of flavonoid tolerance and glycosylation capabilities. Optimization of sucrose metabolism through adaptive laboratory evolution (ALE) and targeted metabolic engineering to reroute glucose metabolism to UDPG further enhances E. coli W's glycosylation abilities. We validated our glycosylation platform for bench‐scale production of chrysin‐7‐O‐glucoside (C7O), a valuable flavonoid glucoside, overcoming key challenges related to the low solubility and bioavailability of its precursor, chrysin. To address bioavailability limitations, we implemented a fed‐batch bioprocess in a 3 L bioreactor which returned 1844 mg/L (3.3 mM) C7O, a specific production rate of 0.17 mmol C7O/g DCW·h and a 25.24 mg/g Yp/s after 76 h. An 82.1% yield (1515 mg/L C7O) post extraction and purification demonstrates the efficiency and scalability of the process for industrial bioproduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Systems Biotechnology Group, Department of Systems Biology, Centro Nacional de Biotecnología, CSIC, Madrid, Spain.
- CNB DNA Biofoundry (CNBio), CSIC, Madrid, Spain.
- Extrasynthese, Genay, France.
- Department of Food Chemistry and Biocatalysis, Wrocław University of Environmental and Life Sciences, Wrocław, Poland.
ORCID-Profile: Darwin Carranza-Saavedra, Jesús Torres-Bacete, Sandra Sordon, Ewa Huszcza, Jarosław Popłoński, Juan Nogales
Förderung
- European Commission
- Agencia Estatal de Investigación
Zitieren
APA
Carranza-Saavedra, D., Torres-Bacete, J., Bouju, E., Nuccio, S., Sordon, S., Huszcza, E., Popłoński, J., de Vaumas, R., & Nogales, J. (2025). Engineering a Robust Escherichia coli W Platform for Scalable Production of Flavonoid‐O‐Glucosides. Microbial Biotechnology, 18(10). https://doi.org/10.1111/1751-7915.70226
Vancouver
Carranza-Saavedra D, Torres-Bacete J, Bouju E, Nuccio S, Sordon S, Huszcza E, et al. Engineering a Robust Escherichia coli W Platform for Scalable Production of Flavonoid‐O‐Glucosides. Microbial Biotechnology. 2025;18(10). doi:10.1111/1751-7915.70226
BibTeX
@article{CarranzaSaavedra2025,
author = {Carranza-Saavedra, Darwin and Torres-Bacete, Jesús and Bouju, Elodie and Nuccio, Sylvie and Sordon, Sandra and Huszcza, Ewa and Popłoński, Jarosław and de Vaumas, René and Nogales, Juan},
title = {Engineering a Robust Escherichia coli W Platform for Scalable Production of Flavonoid‐O‐Glucosides},
journal = {Microbial Biotechnology},
year = {2025},
volume = {18},
number = {10},
doi = {10.1111/1751-7915.70226}
}
EUVIMED